SRNE - Sorrento Therapeutics Reports Promising Data From an Uncontrolled Clinical Trial
Sorrento Therapeutics ' (NASDAQ: SRNE) COVI-MSC seems likes promising therapy for COVID-19 after the first four patients treated with the stem cell therapy were released from the hospital. But in this video from Motley Fool Live , recorded on Feb. 1 , Fool.com contributors Brian Orelli and Keith Speights discuss why investors shouldn't read too much into the initial uncontrolled results.
For further details see:
Sorrento Therapeutics Reports Promising Data From an Uncontrolled Clinical Trial